GlassScriptPhysician profile
John A Mcknight
NPI 1972694503
$2,173.03
in general payments reported to CMS, 2019-2025
16 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $243 · 2021: $216 · 2022: $289 · 2023: $300 · 2024: $342 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $442.31 | 2019-2025 | Wolverine Coronary Cutting Balloon, Avvigo Guidance System, General - Balloon Catheters |
| Abbott Laboratories | $303.60 | 2019-2024 | Jot Dx, Amplatzer Amulet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $264.94 | 2021-2025 | Lifevest |
| Merit Medical Systems INC | $262.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $208.82 | 2021-2024 | |
| Heartflow, INC. | $153.62 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $146.87 | 2019-2025 | |
| Cardiva Medical, INC. | $112.78 | 2025 | Cardiva Vascade 6/7f Vcs |
| Abiomed | $92.69 | 2020-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $61.75 | 2019-2023 | Brilinta |
| Cardiovascular Systems INC. | $41.66 | 2022-2023 | Diamondback Coronary |
| Stryker Corporation | $23.54 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $19.71 | 2024 | Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.88 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcknight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.